Skip to Content

Beta Bionics, Inc.

Securities Class Action

  • Date:
  • 11/3/2026
  • Company Name:
  • Beta Bionics, Inc.
  • Stock Symbol:
  • BBNX
  • Class Period:
  • FROM 7/30/2025 TO 2/24/2026
  • Status:
  • Filed
  • Court:
  • U.S. District Court: Central California

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ:BBNX) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026, both dates inclusive (the “Class Period”). Investors have until November 3, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
 
According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements to the market about Beta Bionics' automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump ("iLet"). The FDA had raised numerous serious issues with the iLet device itself, namely that the device was malfunctioning and dosing patients with dangerously high levels of insulin, causing hypoglycemic events. Thus, contrary to defendants' assertions that the complaints back-filed with the FDA pursuant to the Form 483 were of no moment and entirely benign, they instead numbered in the thousands and included hundreds of life-threatening events requiring significant medical intervention. Nor was the FDA satisfied with Beta Bionics' response to the issue, as Beta Bionics had utterly failed to implement any meaningful corrective actions. When the true details entered the market, the lawsuit claims that investors suffered damages.
 
If you purchased or otherwise acquired Beta Bionics shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Beta Bionics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: